KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBT (2016 - 2025)

Historic EBT for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to -$105.8 million.

  • CRISPR Therapeutics AG's EBT fell 2439.99% to -$105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$525.8 million, marking a year-over-year decrease of 9705.69%. This contributed to the annual value of -$403.9 million for FY2024, which is 12305.02% down from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's EBT is -$105.8 million, which was down 2439.99% from -$207.3 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's EBT ranged from a high of $763.4 million in Q2 2021 and a low of -$207.3 million during Q2 2025
  • For the 5-year period, CRISPR Therapeutics AG's EBT averaged around -$68.7 million, with its median value being -$115.9 million (2024).
  • As far as peak fluctuations go, CRISPR Therapeutics AG's EBT soared by 106291.23% in 2021, and later crashed by 23144.05% in 2024.
  • CRISPR Therapeutics AG's EBT (Quarter) stood at -$143.5 million in 2021, then rose by 15.42% to -$121.4 million in 2022, then surged by 148.79% to $59.2 million in 2023, then tumbled by 231.44% to -$77.8 million in 2024, then crashed by 35.94% to -$105.8 million in 2025.
  • Its EBT stands at -$105.8 million for Q3 2025, versus -$207.3 million for Q2 2025 and -$134.9 million for Q1 2025.